Growth of emerging economies threatens US dominance of generics market, says report

5 October 2016

The USA’s dominance of the global generics market will gradually shift to emerging markets including India, China, and Brazil, according to a new survey.

An extensive survey of 47 generic drug industry experts conducted by business intelligence provider GBI Research sought views on the future of this market, and the report also used the firm's own data, research and analysis to make predictions.

Around 29% of the surveyed experts believed that China would become the highest revenue-generating emerging market for generic drug manufacturers in the next five years, with 23% of respondents predicting that it would be India.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK